Table 2 Tumor response to HD IL-2
| Â | Entire Cohort (NÂ =Â 237) | Cutaneous (NÂ =Â 182) | Mucosal (NÂ =Â 14) | Uveal (NÂ =Â 16) | Other (NÂ =Â 1) | Unknown (NÂ =Â 24) |
|---|---|---|---|---|---|---|
Best Response – no. (%) | ||||||
 CR | 19 (8) | 17 (9) | 1 (7) | 0 (0) | 0 (0) | 1 (4) |
 PR | 24 (10) | 18 (10) | 2 (14) | 1 (6) | 0 (0) | 3 (13) |
 SD | 54 (23) | 37 (20) | 4 (29) | 5 (31) | 0 (0) | 8 (33) |
 PD | 140 (59) | 110 (60) | 7 (50) | 10 (63) | 1 (100) | 12 (50) |
No. of patients with CR or PR | 43 | 35 | 3 | 1 | 0 | 4 |
 Percentage (95% CI) | 18 (13–24) | 19 (14–26) | 21 (5–51) | 6 (0–30) | 0 (−) | 17 (5–37) |
No. of patients with CR, PR, or SD | 97 | 72 | 7 | 6 | 0 | 12 |
 Percentage (95% CI) | 41 (35–47) | 40 (32–47) | 50 (23–77) | 38 (15–65) | 0 (−) | 50 (29–71) |